Quintiles to acquire Eidetics

May 15, 2008 - PRLog -- Quintiles Transnational (Research Triangle Park, North Carolina) has signed an agreement to acquire Eidetics (Boston, Massachusetts), a privately held healthcare market research and consulting firm.  Financial terms were not disclosed.  The transaction is subject to fulfilment of certain conditions of the purchase agreement.  Quintiles expects the deal to be completed by the end of June, the company told Biopharm Development News.

 
Founded 20 years ago, Eidetics provides research-based market insights and data analytics to support business decision-making in drug and medical device development and commercialisation.  Its consultancy services support decisions in areas such as go/no go, clinical trial design, franchise positioning, portfolio development, market segmentation and pricing/contracting strategy.  The firm works across all disease areas, and has a speciality practice in oncology.  It employs around 50 staff.

 
Eidetics will retain its name and remain in Boston.  It will become part of Quintiles Consulting, led by president Jay Norman, strengthening the company’s services in product development, commercialisation and market access consultancy.  Joining Quintiles will allow Eidetics to offer “enhanced clinical, patient and provider data, greater therapeutic depth and access to global resources”, said Eidetics partner Jim Kirk.

… expanding business
Quintiles has been actively expanding its consulting business; the company recently announced the appointment of three new practice leaders and a business development head.  The new leadership team members are:  Dr John Doyle, covering US market access; Dr Adrian K McKemey, US product development and commercialisation; and Dr Jim Featherstone, regulatory, quality, product development and commercialisation, Europe.

Dr Doyle was previously co-founder and president of the health economics and market access consulting firm, Analytica International.  Prior to that, he directed Bristol-Myers Squibb’s oncology and immunology economics research group.  Dr McKemey was previously a principal with Boston Consulting Group, working in the healthcare practice and the BCG Strategy Institute.  Before that, he was a particle physicist, a tenured faculty member at Brunel University (London, UK) and a visiting professor at Stanford University (US).  Dr Featherstone was formerly global head of consulting for Wood Mackenzie’s pharmaceutical and biotechnology practice.  He joined Wood Mackenzie in 2000 after working for British Petroleum’s pharmaceutical division, and pursuing an academic career.

Matt Eberhart has been appointed vice-president, business development, responsible for establishing a global business development framework, leading US business development efforts and acting as internal liaison with the rest of the company.  He was previously an executive management team member at Katalyst, a privately held venture capital and advisory firm.  He has also served as a senior manager and European leadership team member for Deloitte Consulting’s life sciences practice.

# # #

www.jobs4dd.com is a specialist online recruitment service for the clinical trial and drug development sectors. Latest news and jobs in the industry are listed on a daily basis. Latest international clinical research jobs, CRM jobs, regulatory affairs jobs, data management jobs, statistician jobs, pharmacovigilance jobs and many more vacancies are listed on the www.jobs4dd.com website. Visit our news archive section at www.jobs4dd.com/news-archive.php

Website: www.jobs4dd.com